Bergeret-Galley C, Latouche X, Illouz Y G
Aesthetic Plast Surg. 2001 Jul-Aug;25(4):249-55. doi: 10.1007/s002660010131.
DermaLive is a long-term wrinkle reduction product including two types of components: pure hyaluronic acid, produced in cell culture, and an acrylic hydrogel. The product was first marketed in France and the rest of Europe in 1998. We have over three years of experience with this product. Several studies have been conducted simultaneously, mainly in Germany and in France. At present, DermaLive is used in the long-term correction of natural or acquired skin depressions (caused by aging, trauma) or the creation of volume (lips, sunken cheekbones). It provides a worthwhile alternative to good-quality bioresorbable materials (pure hyaluronic acid or collagen)--materials that are so resorbable, in fact, that most patients are ultimately dissatisfied with the results--and to other so-called permanent materials that patients do not tolerate well. Filling involving the use of autologous fat transplantations, which yields satisfactory results, is not appropriate for ambulatory injection and, therefore, will not be examined in detail. The tolerance experienced with DermaLive three years on is, at present, considered highly satisfactory. The wrinkle reduction effect obtained after the first injection is long-lasting with 60% resorption of the initial material. Two or three injections, with an interval of at least three months between each, may be required to bring about the reduction of some wrinkles or the correction of post-scar depressions. Side effects occurring long after the injection are rare (1.2 for 1,000). They appear mainly as palpable nodules occurring about six months after injection. They are treated by intralesional injection of corticoids. DermaLive and DermaDeep are both filler implants with a long-lasting effect designed for corrective and aesthetic surgery. Instruction of use and intervals between injection sessions must be respected. After DermaLive or DermaDeep injection, injections of pure hyaluronic acid (Juvederm or Restylane) for treatment of fine lines and superficial defects yield safe and excellent aesthetic results.
DermaLive是一种长期减少皱纹的产品,包含两种成分:通过细胞培养生产的纯透明质酸和一种丙烯酸水凝胶。该产品于1998年首次在法国及欧洲其他地区上市。我们对该产品已有三年多的使用经验。同时进行了多项研究,主要在德国和法国。目前,DermaLive用于长期矫正自然或后天形成的皮肤凹陷(由衰老、创伤引起)或增加面部容积(嘴唇、凹陷的颧骨)。它为优质的生物可吸收材料(纯透明质酸或胶原蛋白)——事实上这些材料吸收性很强,以至于大多数患者最终对结果不满意——以及其他患者耐受性不佳的所谓永久性材料提供了一种有价值的替代方案。涉及使用自体脂肪移植且效果令人满意的填充方法,不适用于门诊注射,因此本文不会详细探讨。目前认为,使用三年的DermaLive耐受性非常令人满意。首次注射后获得的减少皱纹效果持久,初始材料有60%被吸收。可能需要进行两到三次注射,每次间隔至少三个月,以减少一些皱纹或矫正疤痕后凹陷。注射后很长时间出现的副作用很少见(每1000例中有1.2例)。它们主要表现为注射后约六个月出现可触及的结节。通过病灶内注射皮质类固醇进行治疗。DermaLive和DermaDeep都是具有长效作用的填充植入物,用于矫正手术和美容手术。必须遵守使用说明和注射疗程之间的间隔。在注射DermaLive或DermaDeep后,注射纯透明质酸(乔雅登或瑞蓝)用于治疗细纹和浅表缺陷可产生安全且出色的美容效果。